2-billion-years-old
technology, unleashed.
Extracellular Vesicles from Microalgae (MEV)
as Delivery Systems for Human Therapeutics.
As an innovative Biopharmaceutical Company, we engineer the natural machinery of billion-years-old microalgae to develop novel therapeutics.

2-billion-year-old
technology, unleashed .
Extracellular Vesicles from Microalgae (MEV)
as Drug Delivery Systems for Human Therapeutics.
As a Biopharmaceutical Company, we engineer the billion-years-old natural machinery of microalgae to develop therapeutics delivered by microalgae extracellular vesicles (MEVs).

COMPANY





REPORT
REPORT
2-billion-year-old technology, live.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

COMPANY





REPORT
REPORT



R&D programs
As dramatically seen with the current COVID-19 pandemic, therapeutics against viral and bacterial infections still represent a significant medical problem as new or resistant pathogens emerge. There is a vast, urgent, unmet need to bring rapid and adapted solutions against emerging diseases.

Intranasal
AGS-02 is a siRNA population targeting multiple regions, simultaneously, against S. aureus, covering essential genes, virulence factors, and antibiotic resistance genes.

Intranasal to Synapse
AGS-03 is a siRNA population targeting multiple viral regions simultaneously against SARS-CoV-2, more specifically sixteen regions of the viral genome and host regulatory genes.


Topical
AGS-01 is a siRNA population targeting multiple regions, simultaneously, against P. aeruginosa, namely essential genes, virulence factors, and antibiotic resistance genes.

Smell receptor
CNS (Brain)
AGS-02 is a siRNA population targeting multiple regions, simultaneously, against S. aureus, covering essential genes, virulence factors, and antibiotic resistance genes.

Neuron (synapse)
CNS (Brain)
AGS-03 is a siRNA population targeting multiple viral regions simultaneously against SARS-CoV-2, more specifically sixteen regions of the viral genome and host regulatory genes.

Urinary bladder mucosa
Mucosa (urogenital)
AGS-01 is a siRNA population targeting multiple regions, simultaneously, against P. aeruginosa, namely essential genes, virulence factors, and antibiotic resistance genes.
AGS Tx is an innovative biopharmaceutical company. We develop next generation therapeutics and vaccines (based on mRNA, siRNA, DNA, proteins, small molecules) delivered by extracellular vesicles from microalgae (MEVs).
Technology Platforms
With a strong IP position as well as an experienced and dedicated team onboard, AGS Tx works on proprietary technology platforms including microalgae cell engineering, biomolecule design, biopharmaceutical product development in vitro and in vivo, MEVs manufacturing at lab and pre-industrial scale (AGS-M), MEVs bio-analytics and characterization.
At AGS Tx, we strongly believe our science and technology can make a difference for patients worldwide. Gene and drug therapies are in great need of delivery platforms that can drive them to their therapeutic targets safely and effectively.
Therefore, we aim to explore the potential of our technology, by both staying focused on the R&D challenges that we face and developing our technology platforms and products.
Technology Platform
Our highly versatile, proprietary technology platform can be applied to a diversity of targets and purposes. As part of our initial focus on anti-infectives, we develop microalgae-induced gene silencing therapeutics, delivered by microalgae extracellular vesicles, aimed at killing or blocking the replication of human pathogens.

Microalgae Genetic Engineering
Our proprietary platform enables the generation of stable producer cell lines from genetically engineered microalgae, for therapeutics applications. The microalgae are then used to express custom, targeted RNAi (siRNA or miRNA) which are directly embedded, by the same microalgae, into their own extracellular vesicles.

Antimicrobial Precision Killing
The therapeutic agents (RNAi) produced by our initial set of microalgae cell lines are designed to be pathogen-killers independent of their antibiotic resistance (bacteria) and their immunogenicity or escape mutability (viruses). Welcome the next generation of antibacterial and antiviral biotherapeutics.

Gene Silencing Shotgun
We take advantage of the versatility of RNAi, used to down-regulate the expression of target genes in specific hand-picked gene sequences, and aim at any and all regions, both structural and functional, where essential, pathogenic, or resistance genes are present.
All the action happens simultaneously, like a shotgun.

Natures’ own Delivery System
True to EVs’ natural role as primary communication channel between cells, we engineered our microalgae-based EVs (MEVs) to serve as Drug Delivery System (DDS), to carry, protect, and deliver their cargo right into human or bacterial cells. By design, MEVs can be either generic (targeting a variety of tissues and allowing for multiple administration routes) or specific.

The Ideal Biological System
Microalgae are free from human pathogens (e.g. viruses, mycoplasma), and their MEVs are non-toxic as well as non-immunogenic for humans. Unlike most of the current pharmaceutical industry, which uses animal cells or synthetic biology for the manufacturing of proteins, viral vectors, and EVs among others, our technology offers a safer alternative.

The New Gold Standard
Requiring only light, water, and salts, microalgae-based biologics are produced and purified using inherently clean and simple processes, with low-to-no media supplements, that can easily be scaled-up in compliance with cGMP regulations. Equipped with cutting-edge Photo-Bioreactors (PBRs) and industry-standard Downstream Processing (DSP) tools, we achieve a high-yield, low-cost overall process.







Management team
Advisory Board
Eric QUEMENEUR
(since 2014).
Alex CHANAS
Ron NEWBOLD
(since 2020).
VP External R&D Innovation, PFIZER (2010-2017).
Jérémy PRUVOST
Director, GEPEA.
Co-Director, SPI Doctoral School, Univ. Nantes (2012-2016).
Fayza DABOUSSI
Research Director, INRA.
PARTNERS










Job Openings
AGS Tx is expanding its team and actively seeking candidates for ten newly created positions.
They are talking about us
Let's talk
We welcome biotech companies eager to collaborate, researchers looking to expand our body of knowledge, investors funding the next generation of bio-platforms, and professionals ready to be part of the future of biotech.